Answer
Before and during filgotinib maleate (Jyseleca) treatment, screen for viral hepatitis and monitor for reactivation according to clinical guidelines; clinical studies excluded patients positive for both hepatitis C antibody and hepatitis C virus RNA, or for hepatitis B surface antigen or hepatitis B virus DNA.
Sources for this answer
- Jyseleca 100 mg film-coated tabletsAlfasigma UK Limited (formerly Galapagos Biotech Limited) · emc · SmPC §4.4 Special warnings and precautions for use · Version 20Document updated
Sources checked